Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$3.38
+6.0%		$3.82
$2.03
▼
$7.13
N/AN/AN/A204,734 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$1.14
+6.5%		$1.18
$1.04
▼
$3.08
N/AN/AN/A507,344 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
+5.96%-1.46%-13.33%-3.15%-33.73%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
+6.54%-6.56%-7.32%-4.20%-50.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$3.38
+6.0%		$3.82
$2.03
▼
$7.13
N/AN/AN/A204,734 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$1.14
+6.5%		$1.18
$1.04
▼
$3.08
N/AN/AN/A507,344 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
+5.96%-1.46%-13.33%-3.15%-33.73%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
+6.54%-6.56%-7.32%-4.20%-50.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.00
Hold$11.00225.44% Upside
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.00
Hold$6.00426.32% Upside

Current Analyst Ratings Breakdown

Latest SPRO and GALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/26/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C-) ➝ Sell (D+)
9/14/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/14/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
Compass Point logo
Compass Point
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral
9/14/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
9/14/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$5.00 ➝ $6.00
8/12/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D-) ➝ Hold (C-)
8/11/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A-$0.43N/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A$0.11N/AN/AN/AN/AN/AN/A11/12/2026 (Estimated)

Latest SPRO and GALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.05N/AN/AN/AN/AN/A
11/12/2026Q3 2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.14N/AN/AN/AN/AN/A
8/14/2026Q2 2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.09-$0.14-$0.05-$0.14N/AN/A
8/12/2026Q2 2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.17-$0.16+$0.01-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%

Insider Ownership

CompanyInsider Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
53.00%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
9N/A30.95 millionOptionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25N/A56.55 millionOptionable

Recent News About These Companies

Spero Therapeutics, Inc. Announces Executive Changes
October 27 at 10:37 PM  |  marketscreener.comM
Spero Therapeutics announces planned COO retirement and transition
October 27 at 5:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/spero-therapeutics-announces-planned-coo-retirement-and-transition?utm_source=marketbeat.com&utm_medium=referral
Spero Therapeutics announces key leadership appointments
October 26 at 3:00 PM  |  thepharmaletter.comT
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
October 26 at 9:59 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spero-therapeutics-strengthens-leadership-team-120000418.html
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
October 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-spero-therapeutics-targets-2027-phase-ii-launch-for-sp001-in-igg4-related-disease-2026-10-21/
Spero presents at Chardan, and Spero Therapeutics stock costs EUR 0.99
October 20, 2026  |  ad-hoc-news.deA
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3382113/0/en/spero-therapeutics-to-participate-in-the-chardan-10th-annual-healthcare-conference.html
Spero Therapeutics (NASDAQ:SPRO) Stock Price Breaks Below Two Hundred Day Moving Average - Here's What Happened
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-spero-therapeutics-nasdaq-spro-stock-price-breaks-below-two-hundred-day-moving-average-heres-what-happened-2026-10-13/
Russian plague outbreak could boost these under-the-radar pharma stocks
October 5, 2026  |  invezz.comI
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 4, 2026  |  biospace.comB
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average - What's Next?
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-spero-therapeutics-nasdaq-spro-stock-price-crosses-below-200-day-moving-average-whats-next-2026-10-03/
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374028/0/en/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Spero Therapeutics consensus price target raised 25% to $5.10
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/spero-therapeutics-consensus-price-target-raised-25-to-5-10/ar-AA2dnDXQ
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356262/0/en/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355479/0/en/spero-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investment-conference.html
Spero Therapeutics stock gains on small-cap biotech interest
September 1, 2026  |  ad-hoc-news.deA
Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1.20
August 29, 2026  |  ad-hoc-news.deA
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spero-therapeutics-spro-q2-2026-212842707.html
Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299460-spero-therapeutics-inc-spero-therapeutics-announces-second-quarter-2026-operating-results-and-provides-business-update-399.htm
Spero outlines cash runway into the second half of 2029 following $105M royalty financing
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4632053-spero-outlines-cash-runway-into-the-second-half-of-2029-following-105m-royalty-financing
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935709-spero-therapeutics-inc-spro-q2-2026-earnings-call-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$3.38 +0.19 (+5.96%)
As of 10/27/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$1.14 +0.07 (+6.54%)
Closing price 10/27/2026 04:00 PM Eastern
Extended Trading
$1.11 -0.03 (-2.98%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas